{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T02:51:40Z","timestamp":1721443900128},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"44","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Although essential thrombocythemia (ET) and immune thrombocytopenia (ITP) have different etiologies, 3 previous reports have described ET development in ITP patients, all of whom were positive for the <jats:italic toggle=\"yes\">JAK2<\/jats:italic> V617F mutation. Here, we report the first published case of ITP following ET in the absence of other platelet disorders.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 70-year-old woman with a five-year history of ET with <jats:italic toggle=\"yes\">JAK2<\/jats:italic> V617F mutation treated with hydroxycarbamide for five months presented with petechiae on her limbs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Her platelet count was 3\u200a\u00d7\u200a10<jats:sup>9<\/jats:sup>\/L, with the immature platelet fraction being 29%. White blood cell count and hemoglobin level were normal. Bone marrow examination showed increased number of megakaryocytes, but no morphologic dysplasia in any lineage. G-band analysis revealed no abnormalities. Platelet transfusion and cessation of hydroxycarbamide did not affect the platelet count. Thrombocytopenia was unlikely to have been induced by drugs, heparin, systemic lupus erythematosus, or human immunodeficiency virus. Hence, a diagnosis of ITP was made.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient received oral prednisolone combined with intravenous immunoglobulin.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Her platelet count rose to 310\u200a\u00d7\u200a10<jats:sup>9<\/jats:sup>\/L and remained stable, while her steroid dose was reduced. Further blood tests revealed the presence of antibodies against <jats:italic toggle=\"yes\">Helicobacter pylori<\/jats:italic>, and appropriate treatment was administered. Resumption of hydroxycarbamide did not induce thrombocytopenia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Although ET and ITP have different etiologies, chronic inflammation and immune deregulation underlie both and may play an important role in the progression from one to the other. Further research is warranted to understand the relationship between ET and ITP.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000017766","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T19:38:47Z","timestamp":1572896327000},"page":"e17766","source":"Crossref","is-referenced-by-count":4,"title":["JAK2 V617F-positive essential thrombocythemia with subsequent development of immune thrombocytopenia"],"prefix":"10.1097","volume":"98","author":[{"given":"Yasuhiro","family":"Oda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuku","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiko","family":"Kanbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Kamata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satomi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yotaro","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2019,11]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1749-6632.1965.tb18984.x","article-title":"Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies","volume":"124","author":"Shulman","year":"1965","journal-title":"Ann N Y Acad Sci"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/nm921","article-title":"T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura","volume":"9","author":"Olsson","year":"2003","journal-title":"Nat Med"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood-2002-05-1475","article-title":"Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro","volume":"102","author":"Chang","year":"2003","journal-title":"Blood"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.thromres.2016.06.019","article-title":"JAK2V617F mutation in immune thrombocytopenia","volume":"144","author":"Huang","year":"2016","journal-title":"Thromb Res"},{"key":"R8-20230915","first-page":"3725089","article-title":"Immune thrombocytopenia and JAK2V617F positive essential thrombocythemia: literature review and case report","volume":"2017","author":"Sobas","year":"2017","journal-title":"Case Rep Hematol"},{"key":"R9-20230915","first-page":"14","article-title":"Essential thrombocytemia following immune thrombocytopenia with JAK2V617F mutation","volume":"9","author":"Caocci","year":"2018","journal-title":"Leuk Res Rep"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ejh.12256","article-title":"Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union","volume":"92","author":"Moulard","year":"2014","journal-title":"Eur J Haematol"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajh.23690","article-title":"How common are myeloproliferative neoplasms? A systematic review and meta-analysis","volume":"89","author":"Titmarsh","year":"2014","journal-title":"Am J Hematol"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.2009.07615.x","article-title":"Epidemiology of immune thrombocytopenic purpura in the general practice research database","volume":"145","author":"Schoonen","year":"2009","journal-title":"Br J Haematol"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-03-754119","article-title":"Clinical updates in adult immune thrombocytopenia","volume":"129","author":"Lambert","year":"2017","journal-title":"Blood"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","article-title":"Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?","volume":"119","author":"Hasselbalch","year":"2012","journal-title":"Blood"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2141.2005.05674.x","article-title":"Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases","volume":"130","author":"Panteli","year":"2005","journal-title":"Br J Haematol"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1365-2141.2010.08249.x","article-title":"JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation","volume":"150","author":"Oku","year":"2010","journal-title":"Br J Haematol"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood-2007-12-129262","article-title":"Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab","volume":"112","author":"Stasi","year":"2008","journal-title":"Blood"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/cei.12279","article-title":"Alterations in immune cell subsets and their cytokine secretion profile in childhood idiopathic thrombocytopenic purpura (ITP)","volume":"176","author":"Talaat","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.3324\/haematol.2011.046417","article-title":"The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia","volume":"96","author":"Rocha","year":"2011","journal-title":"Haematologica"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/nature07036","article-title":"Induction and effector functions of T(H)17 cells","volume":"453","author":"Bettelli","year":"2008","journal-title":"Nature"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/eji.201142250","article-title":"Overexpression of ROR\u03b3t under control of the CD2 promoter induces polyclonal plasmacytosis and autoantibody production in transgenic mice","volume":"42","author":"Yoh","year":"2012","journal-title":"Eur J Immunol"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"9358","DOI":"10.1074\/jbc.C600321200","article-title":"STAT3 regulates cytokine-mediated generation of inflammatory helper T cells","volume":"282","author":"Yang","year":"2007","journal-title":"J Biol Chem"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.2353\/ajpath.2009.080987","article-title":"Surveillance of antigen-presenting cells by CD4+ CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications","volume":"174","author":"Andr\u00e9","year":"2009","journal-title":"Am J Pathol"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.4049\/jimmunol.180.3.1405","article-title":"Suppression of mature dendritic cell function by regulatory T cells in vivo is abrogated by CD40 licensing","volume":"180","author":"H\u00e4nig","year":"2008","journal-title":"J Immunol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017766","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:39:45Z","timestamp":1694824785000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000017766"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":27,"journal-issue":{"issue":"44","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000017766","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}